Innospec drops pursuit for UK rival Elementis after takeover approach rejection



© Reuters.

(Reuters) – Innospec Inc said on Tuesday it was no longer considering a possible offer for rival Elementis (LON:) after the British company rejected a 160-pence per share takeover approach from the U.S. chemicals firm.

Innospec said it had sought support from the London-listed company’s board for its offer that would have valued Elementis at about 929.3 million pounds.

Elementis on Tuesday confirmed that it received Innospec’s conditional cash-and-stock proposal on March 31, adding that it significantly undervalued the company.

The 175-year-old London-based company said the proposal was less attractive for its shareholders as a substantial amount of it was in the form of Innospec shares.

The news comes after Sky News on Monday reported that Elementis received a fresh takeover bid from Innospec that valued it at over 1 billion pounds, which sent shares of the British firm soaring as much as 22%.

Elementis shares, however, were trading down 0.9% at 134.3 pence by 1533 GMT. Innospec shares were down 2%.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

See also  AstraZeneca strengthens Lynparza push with prostate cancer data





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here